0.017196 0.000000 0.000000 0.000000 0.017190 0.000000 0.000000 0.000000 0.018249 0.00000 0.00000 0.00000 Whittingham, J.L. Zhang, Y. Zakova, L. Dodson, E.J. Turkenburg, J.P. Brange, J. Dodson, G.G. http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic 16 90.00 90.00 90.00 58.152 58.174 54.797 C3 H7 N O2 89.093 y ALANINE L-peptide linking C6 H15 N4 O2 1 175.209 y ARGININE L-peptide linking C4 H8 N2 O3 132.118 y ASPARAGINE L-peptide linking C3 H7 N O2 S 121.158 y CYSTEINE L-peptide linking C5 H10 N2 O3 146.144 y GLUTAMINE L-peptide linking C5 H9 N O4 147.129 y GLUTAMIC ACID L-peptide linking C2 H5 N O2 75.067 y GLYCINE peptide linking C6 H10 N3 O2 1 156.162 y HISTIDINE L-peptide linking H2 O 18.015 WATER non-polymer C6 H13 N O2 131.173 y ISOLEUCINE L-peptide linking C6 H13 N O2 131.173 y LEUCINE L-peptide linking C9 H11 N O2 165.189 y PHENYLALANINE L-peptide linking C3 H7 N O3 105.093 y SERINE L-peptide linking O4 S -2 96.063 SULFATE ION non-polymer C4 H9 N O3 119.119 y THREONINE L-peptide linking C9 H11 N O3 181.189 y TYROSINE L-peptide linking C5 H11 N O2 117.146 y VALINE L-peptide linking DK Acta Crystallogr.,Sect.D ABCRE6 0766 0907-4449 62 505 10.1107/S0907444906006871 16627943 I222 Crystal Form of Despentapeptide (B26-B30) Insulin Provides New Insights Into the Properties of Monomeric Insulin. 2006 1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 120.0 1 IMAGE PLATE 2002-02-01 MARRESEARCH SINGLE WAVELENGTH M x-ray 1 0.93300 1.0 ID14-2 ESRF 0.93300 SYNCHROTRON ESRF BEAMLINE ID14-2 2383.698 INSULIN 2 man polymer 2842.277 INSULIN 2 man polymer 96.063 SULFATE ION 3 syn non-polymer 18.015 water 65 nat water DESPENTAPEPTIDE-B26-B30 INSULIN DESPENTAPEPTIDE-B26-B30 INSULIN no no GIVEQCCTSICSLYQLENYCN GIVEQCCTSICSLYQLENYCN A,C polypeptide(L) no no FVNQHLCGSHLVEALYLVCGERGFF FVNQHLCGSHLVEALYLVCGERGFF B,D polypeptide(L) n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n HUMAN sample 9606 HOMO SAPIENS 4932 SACCHAROMYCES CEREVISIAE HUMAN sample 9606 HOMO SAPIENS 4932 SACCHAROMYCES CEREVISIAE 1 2.2 45 2.00 20 % ACETIC ACID, 0.05 M SODIUM SULPHATE, PH 2 repository Initial release Version format compliance Version format compliance 1 0 2006-03-03 1 1 2011-05-08 1 2 2011-07-13 INSULIN MUTANT B16 GLU, B24 GLY, DES-B30 , NMR, 20 STRUCTURES R6 HUMAN INSULIN HEXAMER (NON-SYMMETRIC), NMR, 10 STRUCTURES R6 HUMAN INSULIN HEXAMER (SYMMETRIC), NMR, 10 STRUCTURES HUMAN INSULIN MUTANT SERB9GLU INSULIN COMPLEXED WITH 4-HYDROXYBENZAMIDE AN ACTIVE MINI-PROINSULIN, M2PI STRUCTURE OF THE RHOMBOHEDRAL FORM OF THE M-CRESOL/INSULIN R6 HEXAMER STRUCTURE OF THE MONOCLINIC FORM OF THE M -CRESOL/INSULIN R6 HEXAMER THE STRUCTURE OF THE RESORCINOL/INSULIN R6 HEXAMER FIRST PROTEIN STRUCTURE DETERMINED FROM X- RAY POWDERDIFFRACTION DATA FIRST PROTEIN STRUCTURE DETERMINED FROM X- RAY POWDERDIFFRACTION DATA 1.2 A STRUCTURE OF T3R3 HUMAN INSULIN AT 100 K 1.3 A STRUCTURE OF T3R3 HUMAN INSULIN AT 100 K INSULIN AT PH 2: STRUCTURAL ANALYSIS OF THE CONDITIONS PROMOTING INSULIN FIBRE FORMATION. INSULIN (HUMAN) MUTANT WITH PHE B 24 REPLACED BY SER (F24S) (NMR, REPRESENTATIVE PLUS 9 STRUCTURES) INSULIN (HUMAN, DES-PENTAPEPTIDE (B 26 - B 30)) (NMR, REPRESENTATIVE PLUS 14 STRUCTURES) INSULIN (HUMAN) MUTANT WITH PHE B 24 REPLACED BY GLY (F24G) (NMR, REPRESENTATIVE PLUS 8 STRUCTURES) NMR STRUCTURE OF THE HUMAN INSULIN-HIS(B16 ) CRYSTAL STRUCTURE OF DESTRIPEPTIDE (B28-B30) INSULIN INSULIN MUTANT (B1, B10, B16, B27)GLU, DES -B30, NMR, 25 STRUCTURES INSULIN MUTANT A3 GLY,(B1, B10, B16, B27) GLU, DES-B30, NMR, 19 STRUCTURES INSULIN MUTANT A8 HIS,(B1, B10, B16, B27) GLU, DES-B30, NMR, 26 STRUCTURES CRYSTAL STRUCTURE OF AN UNSTABLE INSULIN ANALOG WITH NATIVEACTIVITY. NON-STANDARD DESIGN OF UNSTABLE INSULIN ANALOGUES WITHENHANCED ACTIVITY SOLUTION STRUCTURE OF THE MONOMERIC [THR(B27 )->PRO,PRO(B28)->THR] INSULIN MUTANT (PT INSULIN) NMR STRUCTURE OF HUMAN INSULIN MUTANT ILE- A2-ALA, HIS-B10-ASP, PRO-B28-LYS, LYS- B29-PRO, 15 STRUCTURES NMR STRUCTURE OF HUMAN INSULIN MUTANT ILE- A2-ALLO-ILE, HIS-B10-ASP, PRO-B28-LYS, LYS-B29-PRO, 15 STRUCTURES NMR STRUCTURE OF HUMAN INSULIN MUTANT ILE- A2-GLY, VAL-A3-GLY, HIS-B10-ASP, PRO- B28-LYS, LYS-B29-PRO, 20 STRUCTURES NMR STRUCTURE OF HUMAN INSULIN MUTANT HIS- B10-ASP, PRO-B28-LYS, LYS-B29-PRO, 20 STRUCTURES LYS(B28)PRO(B29)-HUMAN INSULIN MOL_ID: 1; MOLECULE: INSULIN; CHAIN: A, B; ENGINEERED: YES MUTATION: S(B 9)D; MOL_ID: 1; MOLECULE: INSULIN; CHAIN: A, B; ENGINEERED: YES MUTATION: DES-[PHE(B 25)]; T6 HUMAN INSULIN AT 1.0 A RESOLUTION DEHYDRATED T6 HUMAN INSULIN AT 100 K DEHYDRATED T6 HUMAN INSULIN AT 295 K CRYSTAL STRUCTURE OF ALLO-ILEA2-INSULIN, AN INACTIVE CHIRALANALOGUE: IMPLICATIONS FOR THE MECHANISM OF RECEPTOR HUMAN INSULIN HEXAMERS WITH CHAIN B HIS MUTATED TO TYR COMPLEXED WITH PHENOL HUMAN INSULIN HEXAMERS WITH CHAIN B HIS MUTATED TO TYR COMPLEXED WITH RESORCINOL HUMAN INSULIN HEXAMERS WITH CHAIN B HIS MUTATED TO TYR ENHANCING THE ACTIVITY OF INSULIN AT RECEPTOR EDGE: CRYSTALSTRUCTURE AND PHOTO- CROSS-LINKING OF A8 ANALOGUES NMR STRUCTURE OF HUMAN INSULIN UNDER AMYLOIDOGENICCONDITION, 15 STRUCTURES MINI-PROINSULIN, TWO CHAIN INSULIN ANALOG MUTANT: DES B30, HIS(B 10)ASP, PRO(B 28)ASP, NMR, 20 STRUCTURES MINI-PROINSULIN, SINGLE CHAIN INSULIN ANALOG MUTANT: DES B30, HIS(B 10)ASP, PRO(B 28)ASP AND PEPTIDE BOND BETWEEN LYS B 29 AND GLY A 1, NMR, 20 STRUCTURES SOLUTION STRUCTURE OF HUMAN PROINSULIN C- PEPTIDE NMR STRUCTURE OF HUMAN INSULIN MUTANT HIS- B10-ASP, VAL-B12-ALA, PRO-B28-LYS, LYS- B29-PRO, 15 STRUCTURES NMR STRUCTURE OF HUMAN INSULIN MUTANT HIS- B10-ASP, VAL-B12-THR, PRO-B28-LYS, LYS- B29-PRO, 15 STRUCTURES NMR STRUCTURE OF HUMAN INSULIN MUTANT HIS- B10-ASP, VAL-B12-ABA, PRO-B28-LYS, LYS- B29-PRO, 15 STRUCTURES INSULIN (T3R3) COMPLEX WITH TWO ZINC IONS INSULIN (T3R3) (PH 6.4, 0.75 M NACL) COMPLEXED WITH TWO ZINC IONS AND TYLENOL ( 4'-HYDROXYACETANILIDE) INSULIN (T3R3) (PH 5.6, 1.0 M NACL) COMPLEXED WITH TWO ZINC IONS AND TYLENOL ( 4'-HYDROXYACETANILIDE) CRYSTALLOGRAPHIC AND SOLUTION STUDIES OF N- LITHOCHOLYL INSULIN: A NEW GENERATION OF PROLONGED-ACTING INSULINS. HUMAN INSULIN TWO DISULFIDE MODEL, NMR, 10 STRUCTURES STRUCTURAL PROPERTIES OF THE B25TYR-NME- B26PHE INSULIN MUTANT. STRUCTURE OF INSULIN HUMAN INSULIN DISULFIDE ISOMER, NMR, 10 STRUCTURES DIABETES-ASSOCIATED MUTATIONS IN HUMAN INSULIN : CRYSTALSTRUCTURE AND PHOTO-CROSS-LINKING STUDIES OF A-CHAINVARIANT INSULIN WAKAYAMA STRUCTURE OF B28 ASP INSULIN IN COMPLEX WITH PHENOL STRUCTURE OF INSULIN INSULIN, MONOCLINIC CRYSTAL FORM R6 HUMAN INSULIN HEXAMER (SYMMETRIC), NMR, 20 STRUCTURES INSULINE(1SEC) AND UV LASER EXCITED FLUORESCENCE INSULINE(60SEC) AND UV LASER EXCITED FLUORESCENCE NMR STRUCTURE OF HUMAN INSULIN IN 20% ACETIC ACID, ZINC-FREE, 10 STRUCTURES R6 HUMAN INSULIN HEXAMER (SYMMETRIC), NMR, REFINED AVERAGE STRUCTURE R6 HUMAN INSULIN HEXAMER (SYMMETRIC), NMR, ' GREEN' SUBSTATE, AVERAGE STRUCTURE R6 HUMAN INSULIN HEXAMER (SYMMETRIC), NMR, ' RED' SUBSTATE, AVERAGE STRUCTURE PDBE Y PDBE 2006-02-10 REL SO4 SULFATE ION HOH water DECREASES BLOOD GLUCOSE CONCENTRATION SO4 122 3 SO4 SO4 122 A SO4 123 3 SO4 SO4 123 A SO4 122 3 SO4 SO4 122 C HOH 2001 4 HOH HOH 2001 A HOH 2002 4 HOH HOH 2002 A HOH 2003 4 HOH HOH 2003 A HOH 2004 4 HOH HOH 2004 A HOH 2005 4 HOH HOH 2005 A HOH 2006 4 HOH HOH 2006 A HOH 2007 4 HOH HOH 2007 A HOH 2008 4 HOH HOH 2008 A HOH 2009 4 HOH HOH 2009 A HOH 2010 4 HOH HOH 2010 A HOH 2011 4 HOH HOH 2011 A HOH 2012 4 HOH HOH 2012 A HOH 2013 4 HOH HOH 2013 A HOH 2014 4 HOH HOH 2014 A HOH 2015 4 HOH HOH 2015 A HOH 2016 4 HOH HOH 2016 A HOH 2017 4 HOH HOH 2017 A HOH 2018 4 HOH HOH 2018 A HOH 2019 4 HOH HOH 2019 A HOH 2020 4 HOH HOH 2020 A HOH 2021 4 HOH HOH 2021 A HOH 2022 4 HOH HOH 2022 A HOH 2023 4 HOH HOH 2023 A HOH 2001 4 HOH HOH 2001 B HOH 2002 4 HOH HOH 2002 B HOH 2003 4 HOH HOH 2003 B HOH 2004 4 HOH HOH 2004 B HOH 2005 4 HOH HOH 2005 B HOH 2006 4 HOH HOH 2006 B HOH 2007 4 HOH HOH 2007 B HOH 2008 4 HOH HOH 2008 B HOH 2009 4 HOH HOH 2009 B HOH 2010 4 HOH HOH 2010 B HOH 2011 4 HOH HOH 2011 B HOH 2001 4 HOH HOH 2001 C HOH 2002 4 HOH HOH 2002 C HOH 2003 4 HOH HOH 2003 C HOH 2004 4 HOH HOH 2004 C HOH 2005 4 HOH HOH 2005 C HOH 2006 4 HOH HOH 2006 C HOH 2007 4 HOH HOH 2007 C HOH 2008 4 HOH HOH 2008 C HOH 2009 4 HOH HOH 2009 C HOH 2010 4 HOH HOH 2010 C HOH 2011 4 HOH HOH 2011 C HOH 2012 4 HOH HOH 2012 C HOH 2013 4 HOH HOH 2013 C HOH 2014 4 HOH HOH 2014 C HOH 2015 4 HOH HOH 2015 C HOH 2016 4 HOH HOH 2016 C HOH 2017 4 HOH HOH 2017 C HOH 2018 4 HOH HOH 2018 C HOH 2001 4 HOH HOH 2001 D HOH 2002 4 HOH HOH 2002 D HOH 2003 4 HOH HOH 2003 D HOH 2004 4 HOH HOH 2004 D HOH 2005 4 HOH HOH 2005 D HOH 2006 4 HOH HOH 2006 D HOH 2007 4 HOH HOH 2007 D HOH 2008 4 HOH HOH 2008 D HOH 2009 4 HOH HOH 2009 D HOH 2010 4 HOH HOH 2010 D HOH 2011 4 HOH HOH 2011 D HOH 2012 4 HOH HOH 2012 D HOH 2013 4 HOH HOH 2013 D GLY 1 n 1 GLY 1 A ILE 2 n 2 ILE 2 A VAL 3 n 3 VAL 3 A GLU 4 n 4 GLU 4 A GLN 5 n 5 GLN 5 A CYS 6 n 6 CYS 6 A CYS 7 n 7 CYS 7 A THR 8 n 8 THR 8 A SER 9 n 9 SER 9 A ILE 10 n 10 ILE 10 A CYS 11 n 11 CYS 11 A SER 12 n 12 SER 12 A LEU 13 n 13 LEU 13 A TYR 14 n 14 TYR 14 A GLN 15 n 15 GLN 15 A LEU 16 n 16 LEU 16 A GLU 17 n 17 GLU 17 A ASN 18 n 18 ASN 18 A TYR 19 n 19 TYR 19 A CYS 20 n 20 CYS 20 A ASN 21 n 21 ASN 21 A n 1 1 B VAL 2 n 2 VAL 2 B ASN 3 n 3 ASN 3 B GLN 4 n 4 GLN 4 B HIS 5 n 5 HIS 5 B LEU 6 n 6 LEU 6 B CYS 7 n 7 CYS 7 B GLY 8 n 8 GLY 8 B SER 9 n 9 SER 9 B HIS 10 n 10 HIS 10 B LEU 11 n 11 LEU 11 B VAL 12 n 12 VAL 12 B GLU 13 n 13 GLU 13 B ALA 14 n 14 ALA 14 B LEU 15 n 15 LEU 15 B TYR 16 n 16 TYR 16 B LEU 17 n 17 LEU 17 B VAL 18 n 18 VAL 18 B CYS 19 n 19 CYS 19 B GLY 20 n 20 GLY 20 B GLU 21 n 21 GLU 21 B ARG 22 n 22 ARG 22 B GLY 23 n 23 GLY 23 B PHE 24 n 24 PHE 24 B PHE 25 n 25 PHE 25 B GLY 1 n 1 GLY 1 C ILE 2 n 2 ILE 2 C VAL 3 n 3 VAL 3 C GLU 4 n 4 GLU 4 C GLN 5 n 5 GLN 5 C CYS 6 n 6 CYS 6 C CYS 7 n 7 CYS 7 C THR 8 n 8 THR 8 C SER 9 n 9 SER 9 C ILE 10 n 10 ILE 10 C CYS 11 n 11 CYS 11 C SER 12 n 12 SER 12 C LEU 13 n 13 LEU 13 C TYR 14 n 14 TYR 14 C GLN 15 n 15 GLN 15 C LEU 16 n 16 LEU 16 C GLU 17 n 17 GLU 17 C ASN 18 n 18 ASN 18 C TYR 19 n 19 TYR 19 C CYS 20 n 20 CYS 20 C ASN 21 n 21 ASN 21 C n 1 1 D VAL 2 n 2 VAL 2 D ASN 3 n 3 ASN 3 D GLN 4 n 4 GLN 4 D HIS 5 n 5 HIS 5 D LEU 6 n 6 LEU 6 D CYS 7 n 7 CYS 7 D GLY 8 n 8 GLY 8 D SER 9 n 9 SER 9 D HIS 10 n 10 HIS 10 D LEU 11 n 11 LEU 11 D VAL 12 n 12 VAL 12 D GLU 13 n 13 GLU 13 D ALA 14 n 14 ALA 14 D LEU 15 n 15 LEU 15 D TYR 16 n 16 TYR 16 D LEU 17 n 17 LEU 17 D VAL 18 n 18 VAL 18 D CYS 19 n 19 CYS 19 D GLY 20 n 20 GLY 20 D GLU 21 n 21 GLU 21 D ARG 22 n 22 ARG 22 D GLY 23 n 23 GLY 23 D PHE 24 n 24 PHE 24 D PHE 25 n 25 PHE 25 D author_and_software_defined_assembly PQS 4 tetrameric 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 1_555 x,y,z identity operation 0.0000000000 0.0000000000 0.0000000000 1 A SO4 123 F SO4 1 B CB GLU 21 A B CB GLU 21 0 Y 1 B CB GLU 21 B B CB GLU 21 0 Y 1 B CG GLU 21 A B CG GLU 21 0 Y 1 B CG GLU 21 B B CG GLU 21 0 Y 1 B CD GLU 21 A B CD GLU 21 0 Y 1 B CD GLU 21 B B CD GLU 21 0 Y 1 B OE1 GLU 21 A B OE1 GLU 21 0 Y 1 B OE1 GLU 21 B B OE1 GLU 21 0 Y 1 B OE2 GLU 21 A B OE2 GLU 21 0 Y 1 B OE2 GLU 21 B B OE2 GLU 21 0 Y 1 D CB GLU 21 A D CB GLU 21 0 Y 1 D CB GLU 21 B D CB GLU 21 0 Y 1 D CG GLU 21 A D CG GLU 21 0 Y 1 D CG GLU 21 B D CG GLU 21 0 Y 1 D CD GLU 21 A D CD GLU 21 0 Y 1 D CD GLU 21 B D CD GLU 21 0 Y 1 D OE1 GLU 21 A D OE1 GLU 21 0 Y 1 D OE1 GLU 21 B D OE1 GLU 21 0 Y 1 D OE2 GLU 21 A D OE2 GLU 21 0 Y 1 D OE2 GLU 21 B D OE2 GLU 21 0 Y 1 B PHE 1 B PHE 1 1 Y 1 D PHE 1 D PHE 1 1 Y 1 A A O1 O SO4 HOH 123 2021 2.02 1 B B GLY PHE 23 24 A A -149.78 1 D D GLY PHE 23 24 A A -149.95 1 -10.92 1.80 110.60 99.68 B B B N CA CB GLU GLU GLU 21 21 21 B B B N 1 -11.49 1.80 110.60 99.11 D D D N CA CB GLU GLU GLU 21 21 21 B B B N 1 B B CA CB GLU GLU 21 21 0.137 0.022 1.535 1.672 B B N 1 B ARG 22 A -37.76 -38.09 1 D GLU 21 B -69.96 1.04 1 D ARG 22 A -39.05 -39.21 19.59 0.38000 0.00000 0.00000 0.15000 0.00000 -0.53000 0.954 0.935 HYDROGENS HAVE BEEN ADDED IN THE RIDING POSITIONS. RESIDUES B21-B24 OCCUPY TWO DISTINCT CONFORMATION IN EACH OF THE TWO MOLECULES IN THE ASYMMETRIC UNIT. THIS ENTRY CONTAINS ATOMS WITH ZERO OCCUPANCY FOR WHICH THE B-FACTORS HAVE BEEN FIXED AT 20.00. 0.211 0.172 0.174 1.80 41.13 423 8413 4.800 98.1 4.630 0.068 RANDOM 1 THROUGHOUT MOLECULAR REPLACEMENT 0.303 0.122 0.80 0.80 1.20 2-ZINC INSULIN MAXIMUM LIKELIHOOD BABINET MODEL WITH MASK 1.80 41.13 65 784 15 0 704 0.016 0.021 786 0.001 0.020 662 1.490 1.963 1066 0.818 3.000 1530 7.161 5.000 96 36.886 23.684 38 12.433 15.000 118 8.130 15.000 4 0.085 0.200 110 0.008 0.020 894 0.004 0.020 174 0.216 0.200 157 0.173 0.200 653 0.193 0.200 367 0.084 0.200 405 0.198 0.200 26 0.234 0.200 10 0.179 0.200 26 0.179 0.200 9 1.822 1.500 609 2.232 2.000 756 3.616 3.000 360 4.325 4.500 310 0.2150 0.1450 1.84 36 598 20 1.830 25.000 2CEU 9014 2.000 0.04000 1 31.0000 3.900 98.0 0.07000 1.80 1.83 17.000 1 3.70 94.0 refinement REFMAC 5.2.0005 data reduction DENZO data scaling SCALEPACK phasing AMoRE INSULIN Despentapeptide insulin in acetic acid (pH 2) 1 N N 2 N N 1 N N 2 N N 3 N N 3 N N 3 N N 4 N N 4 N N 4 N N 4 N N A GLY 1 A GLY 1 HELX_P A CYS 7 A CYS 7 1 1 7 A SER 12 A SER 12 HELX_P A ASN 18 A ASN 18 1 2 7 B CYS 7 B CYS 7 HELX_P B GLY 20 B GLY 20 1 3 14 C GLY 1 C GLY 1 HELX_P C CYS 7 C CYS 7 1 4 7 C SER 12 C SER 12 HELX_P C ASN 18 C ASN 18 1 5 7 D GLY 8 D GLY 8 HELX_P D GLY 20 D GLY 20 1 6 13 disulf 2.083 A CYS 6 A SG CYS 6 1_555 A CYS 11 A SG CYS 11 1_555 disulf 2.104 A CYS 7 A SG CYS 7 1_555 B CYS 7 B SG CYS 7 1_555 disulf 2.012 A CYS 20 A SG CYS 20 1_555 B CYS 19 B SG CYS 19 1_555 disulf 2.077 C CYS 6 C SG CYS 6 1_555 C CYS 11 C SG CYS 11 1_555 disulf 2.101 C CYS 7 C SG CYS 7 1_555 D CYS 7 D SG CYS 7 1_555 disulf 2.010 C CYS 20 C SG CYS 20 1_555 D CYS 19 D SG CYS 19 1_555 HORMONE INSULIN, DESPENTAPEPTIDE, ACETIC ACID, PH 2, CARBOHYDRATE METABOLISM, DIABETES MELLITUS, DISEASE MUTATION, GLUCOSE METABOLISM, HORMONE, PHARMACEUTICAL given -0.000430 -1.000000 -0.000550 -1.000000 0.000430 0.000370 -0.000370 0.000550 -1.000000 29.09974 29.06617 27.39189 INS_HUMAN UNP 1 P01308 INS_HUMAN UNP 2 P01308 90 110 2CEU 1 21 P01308 A 1 1 21 25 49 2CEU 1 25 P01308 B 2 1 25 90 110 2CEU 1 21 P01308 C 1 1 21 25 49 2CEU 1 25 P01308 D 2 1 25 BINDING SITE FOR RESIDUE SO4 A 122 Software 7 BINDING SITE FOR RESIDUE SO4 A 123 Software 3 BINDING SITE FOR RESIDUE SO4 C 122 Software 8 A GLY 1 A GLY 1 7 1_555 A ILE 2 A ILE 2 7 1_555 A VAL 3 A VAL 3 7 1_555 A GLU 4 A GLU 4 7 1_555 A HOH 2023 H HOH 7 1_555 C GLY 1 C GLY 1 7 1_555 C TYR 19 C TYR 19 7 1_555 A HOH 2021 H HOH 3 1_555 A HOH 2022 H HOH 3 1_555 A HOH 2023 H HOH 3 1_555 A GLY 1 A GLY 1 8 1_555 A TYR 19 A TYR 19 8 1_555 A HOH 2022 H HOH 8 1_555 C GLY 1 C GLY 1 8 1_555 C ILE 2 C ILE 2 8 1_555 C VAL 3 C VAL 3 8 1_555 C GLU 4 C GLU 4 8 1_555 C HOH 2018 J HOH 8 1_555 23 I 2 2 2